Clinical Trials
28 trialsNCT05646862 2026-05-06
INAVO121
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07214662 2026-05-04
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Genentech, Inc.
Phase 1 Recruiting
NCT07235748 2026-02-17
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Servier
Phase 1 Completed
NCT05487235 2025-07-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01585623 2025-03-05
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Bristol-Myers Squibb
Phase 1 Completed
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02609386 2024-01-30
INSPIRE
Brooklyn ImmunoTherapeutics, LLC
Phase 2 Completed
NCT04718740 2023-08-14
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03531762 2023-07-28
Effect of a Proton Pump Inhibitor on the PK of Tepotinib
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03028103 2023-06-26
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Ipsen
Phase 1 Completed
NCT02740712 2023-06-09
DDI
pharmaand GmbH
Phase 1 Completed
NCT04676035 2023-02-09
The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05438303 2023-01-12
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
AstraZeneca
Phase 1 Completed
NCT04959266 2022-09-16
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
AstraZeneca
Phase 1 Terminated
NCT04108676 2022-07-29
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT01596647 2020-12-21
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00210470 2020-12-11
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Brooklyn ImmunoTherapeutics, LLC
Phase 2 Completed
NCT00420615 2020-12-08
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
Novartis
Phase 1 Completed
NCT01287598 2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1 Completed
NCT02500641 2019-06-21
FORWARD
Menarini International Operations Luxembourg SA
Phase 4 Completed
NCT03333824 2019-03-25
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT01517399 2019-02-12
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
Daiichi Sankyo
Phase 1 Completed
NCT01911728 2017-06-26
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
Astellas Pharma Inc
Phase 1 Completed
NCT01539655 2017-05-02
Vandetanib
Sanofi
Phase 1 Completed
NCT02518373 2015-08-07
CC5
Cancer Advances Inc.
Phase 2 Completed
NCT00442741 2012-04-25
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
Novartis
Phase 1 Withdrawn
NCT00942175 2012-02-03
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Takeda
Phase 1 Completed
NCT00298779 2008-06-06
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
Millennium Pharmaceuticals, Inc.
Phase 1 Completed